An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors

Anti-Cancer Drugs

Volumn 18, Issue 3, 2007, Pages 273-276

  Oechsle, Karin ^a   Honecker, Friedemann ^a   Kollmannsberger, Christian ^e   Rick, Oliver ^b   Grünwald, Victor ^c   Mayer, Frank ^c   Hartmann, Jörg T ^d   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Klinik Reinhardshoehe   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Capecitabine; Cisplatin refractory; Germ cell tumor; Relapsed

Indexed keywords

CAPECITABINE; CISPLATIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR GROWTH;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 33846670743     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328011fd99     Document Type: Article

References (17)

1. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777-1781.
2. Hartmann JT, Kanz L, Bokemeyer C. Diagnosis and treatment of patients with testicular germ cell cancer. Drugs 1999; 58:257-281.
3. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997; 79:161-168.
4. Miller JC, Einhorn LR. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17:36-39.
5. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999; 17:512-516.
6. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999; 17:509-511.
7. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weißbach L, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996; 7:31-34.
8. Kollmannsberger C, Rick O, Derigs H-G, Schleucher N, Schoeffski P, Beyer J, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002; 20:2031-2037.
9. Fizazi K, Culine S, Chen I. Oxaliplatin in non-seminomatous germ-cell tumors. Ann Oncol 2004; 15:1295.
10. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Thurley H, et al. Angiogenesis and lymphangiogenesis in stage I germ cell tumors of the testis. BJU Int 2000; 86:80-86.
11. Kegel T, Jordan K, Kellner O, Voigt W, Grothey A, Schmoll HJ. Promising activity of capecitabine in refractory germ cell tumors-rationale and a case. Onkologie 2002; 25:127 (abstr 439).
12. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13:346-353.
13. Rick O, Braun T, Siegert W, Beyer J. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006; 42:1775-1779.
14. Hinton S, Catalano P, Einhorn LH, Loehrer PJ Sr, Kuzel T, Vaughn D, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002; 20:1859-1863.
15. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004; 22:108-113.
16. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors. Ann Oncol 2004; 15:493-497.
17. Jakob A, Bokemeyer C, Knop S, Schupp M, Mayer F, Kanz L. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation: a phase II study. Anticancer Drugs 2002; 13:405-410.